| P50 | author | Anthony Yartel | Q55030489 |
| P2093 | author name string | Bryce D Smith | |
| P2860 | cites work | Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement | Q22305313 |
| | The natural history of hepatitis C virus (HCV) infection | Q27473116 |
| | Self-reported hepatitis C virus antibody status and risk behavior in young injectors | Q27478003 |
| | Clinical practice. Chronic hepatitis C infection | Q28241445 |
| | Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention | Q28286743 |
| | How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact | Q28346016 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 | Q29620136 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Physician nonadherence with a hepatitis C screening program | Q33778635 |
| | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 |
| | Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort | Q33836312 |
| | The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States | Q33892586 |
| | Evaluation of abnormal liver-enzyme results in asymptomatic patients | Q33899029 |
| | Patient acceptance of universal screening for hepatitis C virus infection | Q33924602 |
| | Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests | Q34098829 |
| | Risk behavior disclosure during HIV test counseling | Q34213826 |
| | HCV routes of transmission: what goes around comes around | Q34242211 |
| | Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 |
| | Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. | Q34344995 |
| | Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. | Q34409744 |
| | Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users | Q34795051 |
| | Upper limits of normal for alanine aminotransferase activity in the United States population | Q35713666 |
| | Chronic hepatitis C with normal aminotransferase levels | Q35766858 |
| | Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care | Q35788718 |
| | Natural history of initially mild chronic hepatitis C. | Q35928269 |
| | Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 | Q36100389 |
| | Diurnal variation in serum alanine aminotransferase activity in the US population | Q36532832 |
| | Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels | Q36895203 |
| | Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes | Q37261934 |
| | Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study | Q37491370 |
| | Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. | Q39808476 |
| | Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States☆☆☆ | Q39844102 |
| | Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk | Q40021862 |
| | Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. | Q42635260 |
| | Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. | Q42936033 |
| | Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection | Q42977081 |
| | The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States | Q42988978 |
| | Hepatitis C identification and management by family physicians | Q42995525 |
| | Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. | Q42998370 |
| | Management of hepatitis C patients by primary care physicians in the USA: results of a national survey | Q43034294 |
| | Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection | Q43041409 |
| | Economic model of a birth cohort screening program for hepatitis C virus | Q43047944 |
| | Identification and management of hepatitis C patients in primary care clinics | Q43049186 |
| | Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. | Q43159400 |
| | Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study | Q43269850 |
| | Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence | Q43419544 |
| | Updated definitions of healthy ranges for serum alanine aminotransferase levels | Q44047068 |
| | HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy | Q44381066 |
| | The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. | Q44979610 |
| | Hepatitis C knowledge among primary care residents: is our teaching adequate for the times? | Q45031715 |
| | HCV screening practices and prevalence in an MCO, 2000-2007. | Q45112392 |
| | Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease | Q46682777 |
| | Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. | Q50513280 |
| | Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. | Q51852531 |
| | Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. | Q53516428 |
| | Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy | Q56918825 |
| | Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting | Q59654196 |
| | Persistent hepatitis C viraemia without liver disease | Q72210655 |
| P433 | issue | 3 | |
| P921 | main subject | L-alanine | Q218642 |
| | Hepatitis C virus | Q708693 |
| | birth cohort | Q64532946 |
| P304 | page(s) | 233-241 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | American Journal of Preventive Medicine | Q4744265 |
| P1476 | title | Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels | |
| P478 | volume | 47 | |